Key Facts
- Established in 1971, and endowed by the American businessman, Daniel K. Ludwig
- More than 700 scientific, clinical and support staff
- 2011 operating budget of 116 million dollars; 64% from internal Institute funding and 36% from external funding.
- Active Institute-sponsored or managed clinical trials 17
- 2010 Patents:
- Issued: 14
- Filed: 25
- 2010 Publications by Institute investigators
- 314 primary research articles
- 54 reviews, book chapters and/or commentaries
- Institute party to over 170 license and option agreements with commercial organizations
- Sponsor to over 120 postdoctoral fellows and around 100 PhD students
The Ludwig Institute for Cancer Research Ltd is a non-profit research organization committed to improving the control of cancer through integrated laboratory and clinical research and novel therapeutic strategies based on the emerging understanding of cancer. The Institute translates these strategies into applications for human benefit by coupling discoveries from its basic laboratory research and renowned scientists with strong intellectual property positions, clinical development expertise and the conduct of Institute-sponsored, GCP compliant clinical trials.
The core of the Institute is concentrated at ten research locations two each in Australia, Sweden and the USA, and one each in Belgium, Brazil, Switzerland and the UK. Each research site is led by a Director who is a Member scientist of the Institute and part of the management team.
The LICR Fund Inc is a 501(c)3 organization that exists solely to manage the LICR's endowment. US tax-deductible donations can be made to the LICR Fund to support the work of the Ludwig Institute for Cancer Research Ltd.
